Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Clinical trial NCT03204188 · COMPLETED

Trial details

NCT number: NCT03204188
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

B-Cell Chronic Lymphocytic Leukemia B-Lymphocytic Leukemia, Chronic Chronic Lymphocytic Leukemia Leukemia, Chronic Lymphatic Leukemia, Chronic Lymphocytic, B-Cell Leukemia, Lymphocytic, Chronic Leukemia, Lymphocytic, Chronic, B-Cell Lymphocytic Leukemia, Chronic, B Cell Lymphocytic Leukemia, Chronic, B-Cell

Start date: 2017-09-22
Primary completion: 2022-07-18
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.